Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Cancer Res (2023) 83 (23): 3989–4004.

https://doi.org/10.1158/0008-5472.CAN-23-0694

Published: 01 December 2023

View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Includes: Supplementary data

Journal Articles

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Cancer Res (2021) 81 (4_Supplement): PS11-05.

https://doi.org/10.1158/1538-7445.SABCS20-PS11-05

Published: 15 February 2021

View article titled, Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Journal Articles

Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

John FR Robertson, Iain Moppett, Juan Enrique Bargalló Rocha, Giorgi Dzagnidze, Joanna Harding, Teresa Klinowska, Richard Mather, Alastair Mathewson, Rhiannon Maudsley, Christopher J Morrow, Andrew Saunders, Andy Sykes, Li Zhang, Justin PO Lindemann

Cancer Res (2021) 81 (4_Supplement): OT-09-05.

https://doi.org/10.1158/1538-7445.SABCS20-OT-09-05

Published: 15 February 2021

View article titled, Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

Journal Articles

Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)

Mafalda Oliveira, Maxine Bennett, Ali Khalil, Richard Mather, Rhiannon Maudsley, Sam McGuinness, Christopher J Morrow, Andy Sykes, Li Zhang, Teresa Klinowska, Justin PO Lindemann, Danielle Carroll

Cancer Res (2021) 81 (4_Supplement): OT-09-02.

https://doi.org/10.1158/1538-7445.SABCS20-OT-09-02

Published: 15 February 2021

View article titled, Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)

Journal Articles

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott, Thomas Moss, Steve Stokes, Willem M. Nissink, Christopher J. Morrow, Mandy Lawson, Natalie Cureton, Eric Gangl, Pablo Morentin Gutierrez, Richard Mather, Justin P. Lindemann, Andrew Sykes, David Fisher, Radoslaw Polanski, Danielle Carroll, Aisling Barton Twomey, Teresa Klinowska

Cancer Res (2020) 80 (16_Supplement): 5674.

https://doi.org/10.1158/1538-7445.AM2020-5674

Published: 15 August 2020

View article titled, Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

Journal Articles

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Mandy Lawson, Natalie Cureton, Michelle DuPont, Oona Delpuech, Dawn Trueman, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Jamie Scott, Teresa Klinowska, Christopher J. Morrow

Cancer Res (2020) 80 (16_Supplement): 4379.

https://doi.org/10.1158/1538-7445.AM2020-4379

Published: 15 August 2020

View article titled, Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Journal Articles

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Mandy Lawson, Natalie Cureton, Oona Delpuech, Pei Zhang, Azadeh Cheraghchi-Bashi-Astaneh, Sladjana Gagrica, Dawn Trueman, Gareth Maglennon, Daniel Sutton, Bairu Zhang, Jonathan Cairns, Teresa Klinowska, Christopher J Morrow

Cancer Res (2020) 80 (4_Supplement): P6-04-15.

https://doi.org/10.1158/1538-7445.SABCS19-P6-04-15

Published: 15 February 2020

View article titled, Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Journal Articles

Abstract 4408: Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention

PEDRO Torres-Ayuso, Ewelina Testoni, Natalie L. Stephenson, Anna A. Marusiak, Eleanor W. Trotter, Andrew Hudson, Cassandra L. Hodgkinson, Christopher J. Morrow, Caroline Dive, John Brognard

Cancer Res (2016) 76 (14_Supplement): 4408.

https://doi.org/10.1158/1538-7445.AM2016-4408

Published: 15 July 2016

View article titled, Abstract 4408: Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention

Journal Articles

Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic

Cancer Res (2014) 74 (19_Supplement): 3060.

https://doi.org/10.1158/1538-7445.AM2014-3060

Published: 01 October 2014

View article titled, Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic

Journal Articles

Abstract 5434: Inhibition of monocarboxylate transporter 1 as a therapeutic strategy in small cell lung cancer: target validation studies using the MCT1 inhibitor AZD3965.

Radoslaw Polanski, Cassandra L. Hodgkinson, Daisuke Nonaka, Lynsey Priest, Paul D. Smith, Fiona Blackhall, Christopher J. Morrow, Caroline Dive

Cancer Res (2013) 73 (8_Supplement): 5434.

https://doi.org/10.1158/1538-7445.AM2013-5434

Published: 15 April 2013

View article titled, Abstract 5434: Inhibition of monocarboxylate transporter 1 as a therapeutic strategy in small cell lung cancer: target validation studies using the MCT1 inhibitor AZD3965.

Journal Articles

Abstract 1732: PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition.

Danielle S. Potter, Paul J. Kelly, Olive A. Denneny, Caroline Dive, Christopher J. Morrow

Cancer Res (2013) 73 (8_Supplement): 1732.

https://doi.org/10.1158/1538-7445.AM2013-1732

Published: 15 April 2013

View article titled, Abstract 1732: PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition.

Journal Articles

Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters

Christopher J. Morrow, Mohammad Ghattas, Christopher Smith, Heinz Bönisch, Richard A. Bryce, D. Mark Hickinson, Tim P. Green, Caroline Dive

Cancer Res (2010) 70 (14): 5931–5941.

https://doi.org/10.1158/0008-5472.CAN-10-0694

Published: 14 July 2010

View article titled, Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters

Includes: Supplementary data

Journal Articles

Abstract 1022: PI3-kinase inhibition enhances ABT-737-induced apoptosis in colorectal cancer cell lines

Christopher J. Morrow, Jian-Mei Hou, Caroline Dive

Cancer Res (2010) 70 (8_Supplement): 1022.

https://doi.org/10.1158/1538-7445.AM10-1022

Published: 15 April 2010

View article titled, Abstract 1022: PI3-kinase inhibition enhances ABT-737-induced apoptosis in colorectal cancer cell lines

NARROW

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)

Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Abstract P6-04-15: Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Abstract 4408: Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention

Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic

Abstract 5434: Inhibition of monocarboxylate transporter 1 as a therapeutic strategy in small cell lung cancer: target validation studies using the MCT1 inhibitor AZD3965.

Abstract 1732: PI3K inhibition potentiates ABT-737 induced apoptosis in colorectal cancer cells independent of MCL1 downregulation or AKT/mTOR inhibition.

Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters

Abstract 1022: PI3-kinase inhibition enhances ABT-737-induced apoptosis in colorectal cancer cell lines

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only